

ANNUAL REPORT

2023

Who we are

EASL, the European Association for the Study of the Liver, founded in 1966, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology.

Our vision

Beating liver disease. Promoting liver health.

Our mission

EASL, the Home of Hepatology for everyone engaged in beating liver diseases, is committed to fostering awareness, prevention and the best possible patient care through our strategic pillars.

Our four strategic pillars

- Education: to be the prime resource for liver-related education and professional development of Health Care Professionals at all layers in the health care system, as well as patients.
- Advocacy: to be the advocate of the highest standards of hepatology care for patients and increase public awareness about liver diseases.
- Science: to be a key facilitator of excellence in liver research and liver-related innovation.
- Leadership: to be the recognised platform for collaboration, networking, support and representation for and among hepatology professionals across Europe and beyond.

Table of Contents

1.	Message from our Secretary General and Vice-Secretary	2
2.	EASL Leadership	11
3.	EASL Office	17
4.	EASL Events	19
5.	EASL Impact Projects	21
6.	EASL Schools	22
7.	EASL Studio	23
8.	EASL Community and Membership	25
9.	EASL Awards	27
10.	Financial Report	29
11.	Partners	36

MESSAGE FROM OUR SECRETARY GENERAL AND VICE-SECRETARY

Uniting hepatology

Recasting the EASL strategic mission

The 12 months leading up to this year's EASL Congress in Milan kicked off with an exceptional meeting of the new Governing Board and EASL Office executives in Holte near Copenhagen. In the context of a precarious financial situation and an impassioned demand by our membership for a full recovery plan, our task was nothing less than to recast the [EASL strategic mission](#) and to develop a [business plan](#) to deliver it.

Motivated not only by urgency but also by a fundamental belief in EASL's mission and strengths, it has been a busy year. Thanks to the efforts and support of the Governing Board, Committees, Taskforces, and the community at large we are confident that our investments of time and energy are paying off and that the coming months and years will witness EASL's enduring qualities as the true [Home of Hepatology](#), for all of those with an interest in liver health. Please allow us to share with you the core components of our new strategy and business plan.

To begin with, we all agreed that our common [vision](#) for EASL is one of [Beating Liver Disease and Promoting Liver Health](#).

That day in Holte, the Governing Board reconfirmed that EASL's [mission](#) must be to remain the [Home of Hepatology for everyone engaged in managing liver diseases, committed to fostering awareness, prevention and the best possible patient care through our strategic pillars](#).

There was a moment of reflection and much debate as to how this mission could be achieved, what were our core goals. With unlimited commitment but with time and resource constraints, what strategic pillars or [drivers of change](#) should we pursue to achieve our ultimate ambitions? We agreed upon 4.

EASL STRATEGIC PILLARS



EDUCATION



ADVOCACY



SCIENCE



LEADERSHIP



Education

We are dedicated to being the leading independent provider of unbiased, relevant education and professional development opportunities in liver health practice, research, and prevention.

Our range of educational formats, from open access online learning, events big and small through to bespoke training opportunities, cater to basic scientists, practitioners and allied healthcare professionals at all career stages, as well as to patients and other stakeholder groups.


- Our initiatives aim to enhance knowledge, skills, and competencies in hepatology, ultimately improving patient care and outcomes.
- We are committed to maximising learner engagement through new technologies and methodologies.
- We will remain relevant, conducting constant needs assessments to identify and address emerging topics.
- Our innovative learning environments, online or live, will support vibrant communities of learners, ensuring user-friendly interactivity and where appropriate carry CME accreditation.

Developments in EASL's educational offerings this past year include 4 EASL Schools, 53 and 47 EASL Studio episodes and podcasts, respectively, 2 Molecular Tumour Boards, 5 Journal Clubs, 2 basic techniques in experimental hepatology at a glance hands on videos, 24 EASL Quiz questions and 2 online CME-accredited modules, the launch of the brand new EASL DeepDive webinars and a training course with the European Society of Gastrointestinal Endoscopy.

At EASL Congress 2024 specific educational offerings will include 12 special EASL Studio congress episodes, the Postgraduate Course, the Skills Learning Centres, the first edition of the EASL Genetic Board Round and a session entitled A Core Curriculum in Hepatology: current and future from a European perspective.

The mentorship programme was expanded from two to five mentor/mentee pairs in 2024 to provide more opportunities for motivated community members to apply for this career development programme. At EASL Congress we will be hosting the inaugural EASL Alumni Reunion event, which reconvenes recent EASL Schools, Masterclasses and Fellowship participants for a state-of-the-art lecture on leadership, followed by a networking session.

EASL CAMPUS METRICS 2023



Several major enhancements and extensions are planned for our educational offering in the coming months. Perhaps the most ambitious and transformative of all will be the building of an EASL core curriculum in hepatology, in conjunction with our national associations. Meanwhile, in preparation of the next EASL Congress we will be conducting a broad stakeholder survey to assess what the emerging scientific and educational themes are that the community feels we should address at EASL Congress 2025 in Amsterdam.

To illustrate our commitment to providing first class education to all segments of our membership next year we will be producing two completely new online courses: one designed for and by nurses and allied health care professionals, the other dedicated to prevention, policy and public health. Look out too for more focused educational programming on liver transplantation, primary biliary cholangitis, and cirrhosis.



Advocacy

EASL's enhanced advocacy initiatives are focused on elevating standards and accessibility of hepatology care, driving liver health policy change, and preventing disease through increased public awareness.

Public health has always run through all that EASL does, yet as our specialty and the world around us evolve there has never been a greater need to invest in policy, patient engagement, public health, prevention and advocacy work.

- We advise and influence health policy at European and global levels.
- We convene, support and amplify the voices of patient groups.
- We work to raise public awareness and understanding of liver health.
- We educate hepatologists and related specialists on public health and preventive hepatology.

This year saw many remarkable policy initiatives aiming to significantly reduce the liver disease burden in Europe. These included the Meeting of the EASL Friends of the Liver MEPs in the European Parliament, the 2nd annual liver health side event with the WHO during the World Health Assembly in Geneva, and the launch of the EASL Policy Dialogues.

EASL also made multiple policy statements around preventive strategies on alcohol harm and unhealthy foods, vaccine/preventable cancers, viral hepatitis and migrant health, and HCC surveillance among patients with cirrhosis.

Two major prevention and public awareness initiatives were delivered, the 2nd World Liver Day on 19 April and the 3rd iteration of the Love Your Liver campaign during EASL Congress, not only here in Milan but also in Padua, Rome and Palermo.

EASL does not work alone and nurtures multiple partnerships and alliances with public health organisations such as Euractiv and AWAHR as well as related medical specialty societies. We also continue to deepen collaborations with patient organisations to better understand and incorporate patient experiences and needs into liver disease management.



The coming year will see significant progress in the work of the recently launched EASL Lancet Commission 2.0 and as a new European Commission mandate begins, we will reiterate evidence-based recommendations to the European Union Institutions, to boldly address the human and financial burden of liver disease in Europe. We can no longer ignore the enormous impact on millions of lives across Europe, and on health budgets in every country. We will launch the EASL-led European Alcohol Health Alliance, the EASL HCC Screening Taskforce and hold a Brussels policy event with Euractiv.

We are also excited to say that a bespoke educational programme Public Health, Policy and Advocacy Tools for Preventive Hepatology is in the pipeline.



Science

EASL is an established world-class platform for the delivery, sharing, discussion, development and promotion of scientific knowledge as it relates to liver health. Our platform is used by a global community of scientists united by a common goal of building our understanding, expanding scientific frontiers, raising professional standards and ultimately improving our patient outcomes.

- Our annual EASL Congress remains the truly international liver congress, it is complemented by a range of specialist summits throughout the year – all unique opportunities to present and discover the latest peer-reviewed science in our field.
- Basic science is fully integrated into all EASL activities and well represented at leadership level by an emerging Basic Science Taskforce.
- EASL's commitment to facilitate and promote impactful research projects is reflected in the ongoing support of our EASL Consortia and specific EU Horizon 2020, IHI and Horizon Europe projects with which we partner.
- EASL transforms the latest knowledge into evidence-based clinical practice guidelines which aim to enhance informed decision-making, standardising medical practices, and improving clinical outcomes. We focus on making these guidelines ever more accessible and practical for physicians, healthcare providers, and patients.

EASL CONGRESS 2023: ATTENDANCE AND CONTRIBUTIONS

DELEGATES

6,781
registrations
from

104
COUNTRIES



144

Oral presentations



2,458

Abstracts submitted



1,784

Posters

This year has seen a number of breakthrough science-related achievements. We are proud to have seen not only the launch of new Clinical Practice Guidelines on managing acute-on-chronic liver failure, hepatitis delta, liver diseases in pregnancy, and intrahepatic cholangiocarcinoma but also the long-awaited launch of the EASL Mobile CPG App, soon to feature an AI chatbot. Additionally, we've issued a position paper on liver involvement in patients with Fontan-type circulation. EASL Congress will present the inaugural MASLD guidelines and a new guideline on Genetic Cholestatic Diseases.

Our 2 EASL journals are both vital publications, attracting and disseminating the most influential and relevant research articles in the field of liver research. The Journal of Hepatology has solidified its position as the premier Hepatology Journal, while JHEP Reports remains one of the top journals in the field. Over the past 12 months, we bid farewell to Prof. Jessica Zucman-Rossi as the inaugural Editor-in-Chief (EiC) and we welcomed Prof. Josep M. Llovet as the new EiC. Meanwhile this is Prof. Paolo Angeli's final year as EiC of the Journal of Hepatology and we eagerly anticipate working with the new editorial team.



The Liver Cancer Summit in Rotterdam was a resounding success and this year's EASL Congress promises to mark another step towards full recovery of in person events in the post-COVID era.

The Steatotic Liver Disease (SLD) nomenclature is celebrating its first birthday, it is already endorsed by more than 80 societies worldwide as we witness global uptake and implementation. The fact that it is already cited more than 1,000 times testifies to the impact of the measure.

Next year our scientific agenda will start with the rescheduled EASL SLD Summit in Estoril, Portugal, now supplemented by a 1 day patient pathways consensus conference prior to the main event. Followed a month later by the EASL Liver Cancer Summit in Paris, France in February.

In terms of CPGs we have more in the pipeline, including those for Hepatocellular Carcinoma and Hepatitis B.

As mentioned above we will be conducting a community-wide survey to scope out the range of topics to be covered at EASL Congress 2025, which will take place earlier than usual from 7-10 May in Amsterdam, the Netherlands.





Leadership

EASL is a globally recognised community of people committed to improving liver health and research. We are the global voice of European hepatology, representing the values of all those with an interest in liver health, shaping the hepatology landscape worldwide.


- The EASL community continues to grow robustly, in 2023 comprising over 6,800 individual members who are dedicated to advancing liver health worldwide. Especially encouraging is the significant increase in Trainee / Postdoc and undergraduate members. A sign that the future generation of hepatologists see value in being an active part of the EASL Community.
- We have built and maintain an inclusive, diverse and representative community at every level, from Governing Board through to longstanding members and contributors.
- We welcome and integrate members and societies with various backgrounds, specialties, and career stages, fostering a sense of belonging and collaboration.
- We seek to impact the landscape by nurturing an actively engaged membership, identifying and promoting excellence throughout the hepatology community.
- We encourage and facilitate interprofessional collaboration, recognising the importance of diverse perspectives and expertise in advancing liver health care.
- We develop and maintain institutional relationships with sister societies, related medical disciplines, civil society, nongovernmental organisations, regulatory bodies, and private sector partners.

The last year has seen a number of initiatives through which EASL has pursued its mission to be a leading voice in the world of hepatology. Throughout the year we have worked tirelessly to strengthen our relationships with national associations of hepatology within Europe but also beyond and with our colleagues in related medical specialties.

The Healthy Livers Healthy Lives Global Coalition was formally launched by EASL, AASLD, ALEH and APASL in January 2024. In April 2024 we launched the EASL Artificial Intelligence (AI) Taskforce designed to shape the association's approach to AI for the benefit of members and the wider hepatology community including patients and the general public.

At a regulatory level, EASL has contributed to a number of consultations with the European Medicines Agency and with our global partners we will soon be engaging the WHO on revised ICD coding of liver diseases.

EASL SOCIAL MEDIA METRICS AS OF APRIL 2024



As you will have realised, our 4 strategic drivers of change neatly define our identity:

Education **A**dvocacy **S**cience **L**eadership

At the same time as we recast these 4 strategic objectives, we also recognised the need to adopt and align with some broader [common principles](#) that will guide the way in which we operate and interact in pursuit of our mission. We call these our [EASL Values](#) and they are:



People

We take into account the importance of diversity, equality, and inclusion in every aspect of our work. Variety of perspective and expertise ensure the collective strength of EASL leadership, contributors, office staff, and partners.

- We understand the power of interdisciplinarity: working across various specialties, bringing together professionals and patients from different backgrounds to provide comprehensive care for liver diseases.
- We aim for global outreach and inclusivity in addressing liver health, ensuring that opportunities, resources, education, and advancements are accessible to all regardless of gender, ethnicity, nationality, disability, religion, sexual orientation, socio-economic background, or age.
- Our approach is codified in documentation and processes such as a Diversity, Equality, and Inclusion (DEI) Policy, HR Policy and the revised EASL Code of Conduct.





Planet

Sustainability must be imbedded in all leadership and operational practices, ensuring that EASL's activities contribute positively to environmental, social, and economic sustainability.

- We pursue energy efficiency in our operations and prioritise sustainable practices.
- While we will always offer digital alternatives our or in-person events are designed with environmental considerations, and we aspire to signing the Net Zero Carbon Events pledge.
- Our planned EASL office building refurbishment is set to achieve the CEBEG+ label for low energy consumption and the use of 100% renewable energy, with a significant portion produced on-site.
- We also collaborate closely with suppliers, partners, and businesses that support our sustainability and legacy objectives. Through initiatives such as Love Your Liver, EASL not only aims to minimise its environmental impact but also to leave a positive, sustainable legacy in each event host city.



Purpose

Everything that EASL does is driven by a purpose or intrinsic mission as defined in the strategy above. But in today's context the emphasis here is on EASL itself being fit for purpose.

- The EASL Office and wider administrative apparatus must be fully accountable to the Governing Board and membership.
- The highest standards of governance, business practice and customer service are required to ensure that the association has the means with which to pursue our goals.
- There is a strict alignment to established processes, rigorous cost containment and effective fundraising.

Business Analysis Task Force

Having recast our mission, vision, strategic objectives and core values, the Governing Board appointed a Task Force whose remit was to [re-establish financial balance in EASL's financial year 2024](#) and to lay foundations for [sustainable growth](#) in the future. The exercise was designed to generate the least possible negative impact on the value created by EASL for its members, stakeholders, and the community. The Task Force provided [common understanding and direction](#) for the organisation, encouraging broader volunteer ownership and accountability, and enhancing EASL office alignment with the mission.

The resulting 2024 budget was formally approved by EASL members on 28 November 2023, it was essentially a recovery budget to consolidate EASL and provide a basis for the period 2024-2026 while maintaining business continuity.

- We factored into our budget a [20% drop of event attendance](#) compared with pre-COVID years but have sought to maintain a similar level of industry support.
- Structural and enduring adjustments in all our fixed expenses have been prioritised, including a [reduction of EASL Office headcount](#) (from 35.92 FTE to 30.07 FTE).
- We have [consolidated our HR, IT and Finance Departments](#) and largely eliminated the use of external consultants.
- We were able to partially [rescale event cost structures](#) in line with attendance assumptions and have reduced many discretionary event expenses.
- Additional operational savings have been made across all business units through ongoing cost savings via [contract and supplier renegotiations, streamlining and prioritisation](#).
- We also foresee the implementation of an [enhanced audit](#), a rigorous [internal financial control system](#) and [key performance indicators](#) that will be closely monitored.

Since July 2023 EASL leadership and staff have worked hand in hand to honour the commitments of the Business Analysis Task Force while ensuring business continuity and serving the community. This has been a time to concentrate on delivering the essentials but also to plan for the future.

As we write the EASL Congress is just weeks away, we invite you to join us at the [EASL General Assembly](#) in Milan on 7 June at 18:45 for an update on progress to date and perspectives for the coming years.



SECRETARY GENERAL
Aleksander Krag



VICE-SECRETARY
Debbie Shawcross

EASL LEADERSHIP

EASL Governing Board

In the past year, EASL has undergone significant transformations to adapt to the evolving landscape post-COVID. Recognising the importance of meticulous oversight and financial stability, we appointed a Business Analysis Task Force. This task force diligently monitors all EASL operations, ensuring not only financial stability but also optimising our business strategies

for enhanced efficacy. We thank Prof. Thomas Berg as his term as Secretary General concluded, and we extend a warm welcome to Prof. Aleksander Krag, our new EASL Secretary-General. Additionally, we express our deepest gratitude to Prof. Ulrich Beuers, our exiting Educational Councillor, and Prof. Saskia van Mil, a valued member of the

Scientific Committee. Their dedicated service has greatly contributed to the success of our Governing Board. These transitions and acknowledgments signify our commitment to robust governance and effective management. As we move forward, guided by the trust of our members, we continue to shape a resilient and forward-thinking EASL.

Management Committee

Secretary General



Aleksander Krag
Denmark

Vice-Secretary



Debbie Shawcross
United Kingdom

Scientific Committee



Tobias Böttler
Germany

Treasurer



Francesco Negro
Switzerland

Treasurer-Elect



Massimo Pinzani
Italy

Educational Councillor



Sven Francque
Belgium

Public Health Councillor



Maria Buti
Spain

Public Health Councillor-Elect



Shira Zelber-Sagi
Israel

External Affairs Councillor



Francesco Paolo Russo
Italy

Internal Affairs Councillor



Ahmed Elsharkawy
United Kingdom

Scientific Committee



Tobias Böttler
Germany



Virginia Hernández-Gea
Spain



Ana Lleo
Italy



Jean-Charles Nault
France



Bogdan Procopet
Romania



Rui Castro
Portugal



Eric Trépo
Belgium



Sarwa Darwish Murad
The Netherlands

- Nominations and appointment of two [new members](#): Sarwa Darwish Murad and Rui Castro
- Engagement with [online and onsite events](#)
- Reviewing, commenting on, and developing [programmes](#) for events and summits
- Coordinating the development of [Clinical Practice Guidelines](#)
- Providing input on the allocations of [fellowships and grants](#)
- Improving [abstract review system](#), ensuring a more homogeneous evaluation process across reviewers

Educational Committee



Sven Francque
Belgium



Jesus Bañales
Spain



Henning Grønbaek
Denmark



Krista Rombouts
United Kingdom



Verena Keitel
Germany



Josep M. Llovet
Spain



Rajeshwar Mookerjee
United Kingdom

- Nomination and appointment of [Sven Francque as Educational Councillor](#)
- Growth in [EASL Campus](#): 12,200+ resources and 328,361 page views from 181 countries
- Event and CPG [Slide Decks](#), the [EASL Quiz](#) series, EACCME accredited [online courses](#) and modules, offering blended learning
- Launch of EASL Campus Connect, a new networking platform enabling comments and discussion threads on educational resources
- Launch of [EASL Studio](#) seasons 4 and 5.

Policy, Public Health and Advocacy Committee



Maria Buti
Public Health
Councillor
Spain



Shira Zelber-Sagi
Public Health
Councillor-elect
Israel



Peter Jepsen
Denmark



Loreta Kondili
Italy



Jeffrey Lazarus
Spain



Frank Murray
Ireland



Jörn Schattenberg
Germany

- Nomination and appointment of [Shira Zelber-Sagi](#) as EASL Public Health Councillor-Elect.
- Launch of the [Hepahealth II](#) report: Preventing liver disease with policy measures to tackle obesity and alcohol consumption.
- Launch of the [EASL-Lancet Commission 2.0](#): Prevention, case-finding and early diagnosis to reduce liver-related mortality
- Establishment of the [Healthy Livers, Healthy Lives Coalition](#) and its first activities: Steatotic Liver Disease – the missing piece in the NCD puzzle [webinar](#) WHA-77 side event in May 2024.
- Active participation in [World Hepatitis Day](#) on 28 July.
- Active participation in the [Awareness Week on Alcohol Related Harm](#) (AWARH).
- Active participation in [Liver Cancer Awareness Month](#) October 2023.
- Celebration of [World Liver Day](#) on 19 April 2023 & 2024.
- [EASL Policy Dialogues](#) Season 2 and 3, featuring talks on SLD, PBC, the European Health Data Space, Hepahealth II, spotlight on Hepatitis D health literacy, and inequality in liver care.
- Nomination and appointment of [José Willemse](#), replacing Marko Korenjak, as patient representative on the Policy, Public Health, and Advocacy Committee.

Patient synergies



- 10 European umbrella patient organisations engaged in liver diseases as of April 2024.
- EASL Patient Forum held in June 2023, during the EASL Congress.
- Participation in [World Liver Day 2023](#), press conferences at the EASL Congress, Healthy Livers, Healthy Lives events and webinars.
- Welcoming [Fatty Liver Alliance](#): new patient synergy partner.
- Patient engagement at all levels of EASL activity.

EU-Funded Projects



- EASL Supported 8 major EU-funded projects with their communication and dissemination.

Ethics Committee



Mark Thursz
Ethics Committee Chair
United Kingdom



Tom Lüdde
Germany



Valérie Paradis
France



Herbert Tilg
Austria



Maria Berenguer
Spain

- Nomination and appointment of Tom Lüdde as Ethics Committee member.
- We express our gratitude to Christian Trautwein who finished his term in the ethics committee.
- Yearlong monitoring and management of interests at EASL leadership level.
- Regular review of Clinical Practice Guidelines panels.
- Engagement in BioMed Alliance Europe's Code of Conduct Working Group.

EASL Journals

JOURNAL OF HEPATOLOGY



Paolo Angeli
Editor-In-Chief
Italy



Patrizia Burra
Deputy Editor
Italy



Vlad Ratziu
Co-editor
France



Bruno Sangro
Co-Editor
Spain



Frank Tacke
Co-Editor
Germany



Stefan Zeuzem
Co-Editor
Germany

- As the official journal of EASL, Journal of Hepatology provides an international forum for the publication of original articles, reviews and letters to the Editor describing basic laboratory, translational, and clinical investigations in hepatology.
- 2024 is [Prof. Paolo Angeli](#)'s final year as Editor-in-Chief of the Journal of Hepatology and we eagerly anticipate working with the new editorial team.
- EASL's Journal of Hepatology 2022 impact factor is 25.7.

JHEP REPORTS



Josep M. Llovet
Editor-In-Chief
Spain



Xavier Forns
Deputy Editor
Spain



Arndt Vogel
Co-editor
Canada



Jacob George
Co-Editor
Australia



Sophie Lotersztajn
Co-Editor
France

- We bid farewell to [Prof. Jessica Zucman-Rossi](#) as the inaugural Editor-in-Chief (EIC) and we welcomed [Prof. Josep M. Llovet](#) as the new EIC.
- In May 2019 EASL launched a new open-access journal, JHEP Reports, with the ambition of establishing a top-10 journal in the field of gastroenterology and hepatology.
- EASL's JHEP Reports 2022 impact factor is 8.3.

EASL Nurses and AHP Task Force



Malene Barfod
O'Connell
Denmark



Sonja Beckmann
Switzerland



Nuria Fabrellas
Spain



Kate Hallsworth
United Kingdom



Gemma Iserte
Spain



Kathryn Jack
United Kingdom



Denise Schäfer
Austria



Jennifer Towey
United Kingdom

- We welcome [three new members](#): Sonja Beckmann, Kate Hallsworth, Gemma Iserte.
- Full day Nurse & AHP Forum at EASL Congress 2023.
- The [Rising Star Award](#) at EASL Congress 2023 was awarded to Marta Carol Perdiguier. This award aims to recognise excellence in nurses and Allied Health Professionals in hepatology.

EASL YI Task Force



Marta Alonso
Spain



Mattias Mandorfer
Austria



Johanne Poisson
France



Pedro Rodrigues
Spain



Philipp Schwabl
Austria



Thomas Marjot
United Kingdom

- We welcome [three new members](#): Marta Alonso, Thomas Marjot, Pedro Rodrigues.
- Dedicated [YIs Symposium and YI-led workshops](#) at EASL Congress 2023 and EASL Congress 2024.
- Two [YI webinars](#) on: Navigating through an academic career: Step-by-step and Translational Research.
- Selection of two recipients of the 2023 [Emerging Leader Award](#): David Pinato and Lung Yi Mak.

EASL AI Task Force



Julien Calderaro
France



Jakob Kather
Germany



Tom Lüdde
Germany



Thomas Marjot
United Kingdom



Raquel Perez-Lopez
UK



Debbie Shawcross
United Kingdom



Ashley Spann
USA



Eric Trépo
Belgium

- The AI Task Force will aim to advise the EASL Governing Board in [Research, Education, Clinical decision making, EASL events, Journals, and industry collaboration](#)

EASL OFFICE

EASL Office, April 2024

EASL fosters a workplace that is as diverse, equitable, and inclusive as it is forward-thinking and environmentally conscious. In 2023, we boast a team of 34 dedicated staff members, of which 24 are female and 10 male with perfect gender balance achieved at EASL Office Management level. Our team is as varied as it is skilled, representing 14 different nationalities, fluently conversing in 16 languages, with 7 staff members holding scientific doctorates. We have seen a positive impact on our workforce through flexible working hours and the possibility of remote work, boosting productivity and reinforcing the association's dynamism.

These arrangements also encourage the use of public transport, light mobility options, carpooling and paper smart practices. Our competitive remuneration package coupled with a solid pension plan has been crucial in attracting and retaining top talent. The emphasis on job security, seamless integration into the EASL Office team, and active involvement in EASL's leadership governance has nurtured a sense of belonging and commitment among our staff. Our one-to-one management and mentoring approach has carved pathways for career development, offering guidance and ample opportunities for professional growth. In 2024 EASL's office building

refurbishment is foreseen, with the achievement of the CEBEG+ label for low energy consumption, including the use of 100% renewable energy – with 30 % produced on-site a milestone to look forward to. Moreover, through diligent supply chain management and strategic negotiations we have identified avenues to reduce costs without compromising quality and our environmental responsibilities. The planned building renovations have 3 clear goals; 1. Have a building that meets Swiss energy standards 2. Improve its real estate value 3. Drastically reduce the operating costs of the building.



Management & administration

Executive Director



Ben
Hainsworth

Executive Assistant



Laurence
Comont

Human Resources



Sophie
Fux

Finance & Administration



Laurent
Jacquod



Mehdi
Boudjani



Estelle
Pappes

Publications



Joel
Walicki



Duncan
Anderson



Pablo
Echeverria



Kristina
Jajcevic



Sarita
Batthacharya

Science & Education



Laurent
Perrin



Elinam
Gayi



Laura
Daguerre



Louis
Tischhauser

Scientific Programme



Patricia
Pochelon



Céline
Santo



Rocío
Daviña
Núñez



Katerina
Katsarou

Policy & Public Health



Morgane
Guex



Maraika
Black

Events & Operations



Carina
Schmidt



Claire
Chombeau



Christophe
Abetint

Business Development



Olga
Kruger



Laudina
Asomaning



Géraldine
Fankhauser



Gisela
Valky-Pons



Naomi
Siguenza

Association & Community Services



Wouter
Kruijs



Oliver
Cole



Adonia
Dhanjal



Chiara
Hartmann

EASL EVENTS 2023

EASL events are recognised worldwide for their scientific excellence and for covering the full spectrum of hepatology.



EASL Liver Cancer Summit 2023 Estoril, Portugal and online 20-22 April

647 delegates from 48 countries

A comprehensive summit that delved into current knowledge and future directions in hepatocellular and cholangiocellular carcinoma, covering advances in pathogenesis, early detection, multidisciplinary therapies, and staging.



EASL SLD Summit 2023 Prague, Czechia and online 21-23 September

490 delegates from 55 countries

The summit on Steatotic Liver Disease examined diverse topics including MASLD diagnosis, advances in liver biopsy utilisation and biomarkers, controversies surrounding non-invasive tests, the multifaceted nature of MASH, challenges of MetALD, novel therapeutic targets like siRNA and gene targeting, public health awareness, and initiatives such as the Healthy Livers, Healthy Lives roadmap.



EASL Congress 2023, Vienna, Austria and online 21-24 June

6,781 participants from 104 countries

A groundbreaking event for the global hepatology community covering 8 tracks and offering hands-on sessions, symposia, workshops, meet-the-expert sessions and more.



EASL IMPACT PROJECTS


Value creation at EASL does not stop at its members, partners, and delegates. EASL is committed to providing a long lasting, positive impact on the lives of those who are connected to its events, as well as all the people living and working in the communities who host them.

Love Your Liver is designed to raise awareness for liver health, promote early detection and care, and build local professional capacities in the hepatology field. Each year, the EASL team organises projects tailored to the local community hosting the EASL Congress. These initiatives directly work towards EASL's goal of reducing liver disease burdens across Europe, promoting liver health, and catalysing change in the meetings industry to

encourage more socially responsible event practices. At EASL Congress 2023, the LOVE YOUR LIVER projects can attribute their success to all EASL partners both within and out of Austria. At EASL Congress 2023, Love Your Liver initiatives demonstrated EASL's commitment to Vienna by promoting liver health awareness and enhancing professional capacities in hepatology. These projects, tailored to local needs, included interactive sessions at schools, a Town Hall event, and a mobile health check clinic offering free liver screenings. Collaborating with local partners like the Vienna Convention Bureau and the Vienna Board of Education, EASL developed liver health resources for teachers,

empowering them to educate students about liver health. The Town Hall event brought together speakers from diverse health professions to discuss challenges and opportunities for liver health in Vienna, fostering collaboration across disciplines.

The mobile health check clinic provided free liver screenings throughout the congress, supported by certification training for local nurses and a recent medical graduate. Through these impactful projects, EASL strengthened partnerships and demonstrated its commitment to promoting liver health, early detection, and professional development in Vienna.



EASL SCHOOLS

2023

The EASL Schools help train the next generation of hepatologists and scientists. Through individual work, collaborative teamwork and discussions with faculty, students gain invaluable insight into new experimental techniques and clinical approaches.

Diagnostic and treatment challenges in “difficult-to-manage” patients with autoimmune hepatitis and primary biliary cholangitis

- 30 June – 1 July 2023, Larissa, Greece 25 students from 11 countries
- Organisers: George Dalekos, Pietro Invernizzi, Dina Tiniakos

Alcohol-related liver disease: diagnosis, risk stratification and management

- 7–8 July 2023, Odense, Denmark 25 students from 14 countries
- Organisers: Mads E. Israelsen, Aleksander Krag, Maja Thiele

Clinical dilemmas in cirrhosis: an approach from the evidence to the decision

- 7–8 July 2023, Madrid, Spain 25 students from 13 countries
- Organisers: Agustín Albillos, Rafael Bañares, José Luis Calleja, Rosa Martín-Mateos, Javier Zamora

Basic Science School: Microbiome in chronic liver disease

- 27–29 Sept 2023, London, UK 25 students from 14 countries
- Organisers: Roberta Forlano, Pinelopi Manousou, Julian Marchesi, Benjamin Mullish, Debbie Shawcross, Mark Thursz, Palak Trivedi



EASL STUDIO



EASL is keeping pace of an ever-changing society and a rapidly evolving digital landscape, with the launch of a weekly EASL Studio episode, showing commitment to hosting experts' opinion to all those interested in the liver, no matter their location.

This live broadcast, ongoing since 2021, includes interviews, debates, and roundtables on

multidisciplinary topics, as well as special studio editions, live from EASLs congresses and summits, during which experts share their perspectives and key messages on the latest science in clinical practice, prevention, and patient care.

The aim of EASL Studio is to:

- Provide a short comprehensive overview

and introduction into relevant topics.

- React to current events as they happen
- Gather multiple stakeholders around specific topics.
- Give a voice to members of the EASL community.
- Engage the EASL community through live tweeting and online discussions.



Seasons 4 + 5 of EASL Studio and EASL Studio during Congress



53 episodes in 2023



37,500+ cumulative views



223 international experts from 37 countries



123 countries in the audience



16 Industry Partners and 14 sponsored episodes



45 podcasts for 18,685 downloads



Listened in 63 countries

EASL Studio Editorial Board

Aleksander Krag, Odense
University Hospital, Denmark

Debbie Shawcross, King's College
London, UK

Thomas Berg, University of Leipzig,
Germany

Ahmed Elsharkawy, Queen
Elizabeth Hospital, UK

Paolo Angeli, University of Padova,
Italy

Maria Buti, Vall d'Hebron
Barcelona Hospital, Spain

Kathryn Jack, Nottingham
University Hospitals NHS Trust, UK

Rajiv Jalan, University College
London, UK

Verena Keitel, University Hospital
Magdeburg, Germany

Pierre-Emmanuel Rautou, Beaujon
Hospital, Clichy & Paris-Cité
University & INSERM, France

Thomas Reiberger, Medical
University of Vienna, Austria

Pedro Rodrigues, Biodonostia
Health Research Institute, San
Sebastian, Spain

Anna Saborowski, Hannover
Medical School, Germany

Oren Shibolet, Tel-Aviv Medical
Center and Tel-Aviv University,
Israel

Shira Zelber Sagi, School of Public
Health, University of Haifa & Tel
Aviv Medical Center, Israel



COMMUNITY AND MEMBERSHIP

This year has been another remarkable period of growth for EASL, with our membership expanding steadily to surpass 6,800 dedicated individuals in 2023. As we continue to foster our community, we have actively participated in the annual congresses of key international and national societies, including ALEH, APASL, AASLD, INASL, AISF, and UEG.

These engagements have been instrumental in connecting with like-minded professionals. The strength of our association truly lies in our numbers and

diversity; our MyEASL Community now encompasses over 47,000 people from 175 countries. In 2022, we launched a new membership model aimed at making EASL more inclusive and accessible, particularly focusing on the next generation of hepatologists, as well as nurses, allied health professionals, and patients.

We've significantly reduced membership fees for trainees, postdocs, and nurses, and introduced special rates for professionals from emerging economies, while offering

complimentary membership to those from resource-limited economies.

Our goal is to build a stronger, more representative community that can achieve more and deliver superior services to all members.

We extend our deepest gratitude to our members for their ongoing commitment and trust, as they are the backbone of our collective success and the future of hepatology.



EASL™
The Home of Hepatology

Let's unite
Hepatology

Discover your
membership benefits!



Become a member today





119
countries

6,861
members

37
national
associations

TOP 10 COUNTRIES



EASL AWARDS

EASL Recognition Awards 2023

Every year at our annual congress, EASL acknowledges major scientific contributions made by scientists in the field of liver research. The EASL Governing Board selects nominees and the recipients receive their awards in the presence of the liver community, during the annual EASL meeting.



Julia Wendon
United Kingdom




George Papatheodoridis
Greece



Antonio Bertoletti
Italy

EASL Emerging Leader Awards 2023

The EASL Emerging Leader Award is a yearly award specifically dedicated to young fellows, up to 40 years of age, who are active members of EASL. Every year, two Young Investigator Awardees are elected, based on their international liver research achievements to date.



David Pinato
United Kingdom



Lung Yi Mak
Hong Kong

EASL Innovation Award 2023

The “EASL Innovation Award” was presented during the EASL Congress 2023 in Vienna. This award recognises significant scientific contributions from healthcare professionals in the field of liver disease and conveys the gratitude of the society for their innovation. The award was presented to Koichi Tanaka for his pioneering strides in liver transplantation and hepatology, radically transforming the field, envisaging new clinical opportunities and offering pathophysiological insights .



Koichi Tanaka
Japan

EASL Rising Star Award 2023

The Nurses & AHPs Task Force wishes to provide a platform to showcase an emerging liver nurse or AHP whose focus is on putting people with, or at risk of, liver disease at the heart of practice. With this initiative, the task force recognises the many talented liver nurses and AHPs who contribute to service delivery, clinical excellence, leadership, audit, innovation, education, and research.



Marta Carol Perdiguer
Spain

EASL Daniel Alagile Award 2023

The Daniel Alagile Award is given to a promising, young scientist, exploring the frontiers of paediatric or adult genetic cholestatic diseases. It is awarded to an individual who holds a PhD and/or an MD and with a full-time position at a European institution, poised to take his/her research to the next level.

The award is supported by Theravia.



Scott Waddell
United Kingdom

FINANCIAL REPORT

Treasurer's Report

Dear members,
It is my honour to write this Treasurer's Report on EASL's 2023 financial accounts.

At variance with an approved 2023 budget, foreseeing an essentially breakeven result, the final, audited 2023 financial figures show an operating loss of 553,213 EUR. Several factors led to this shortfall, detailed below.

The EASL Congress 2023 industry income was on target, and although the registration-related revenues were down by about 20% vs expectations – signalling that no return to pre-COVID registration volumes can be assumed for the coming years – the event came in just above budget at EUR 3,506,463, emphasising the strict control on expenses carried out by the office team.

The EASL Liver Cancer Summit 2023 and the monothematic conference on Biliary Fibrosis have performed well. However, the EASL Steatotic Liver Disease Summit held in Prague fell short of expectations, financially speaking, with a loss of 57,967 EUR, compared to a budgeted positive result of 95,475 EUR, due to poorer than anticipated registration and industry results.

Education-related revenues from industry were below budget, mainly due to lower sales of EASL Campus-related opportunities and EASL Studio sponsorship. While expenses were significantly reduced, the gap widened from the interim forecast because significant incomes reported according to the date of signature in FY 2023 had to be re-allocated to FY 2024 in line with the term of delivery and project milestones. Those revenues will therefore appear in the financial year 2024.

Revenues generated from membership and our two journals were both better than expected. Membership fees brought in 764,105 EUR, an ~8% increase with respect to 2022. Our publishing unit ended the year with a result more than 140,364 EUR vs budget (+23%). These improvements were due to a thorough investigation of actual incomes from membership, and to the JHEP Reports results.

The Policy, Public Health, and Advocacy result was negatively affected by expenses related to projects not initially planned on this budget line, namely the WHO Side Event (which represented a net cost of about 50,000 EUR) and the retroactive costs of the Hepahealth II project, the last

instalment (initially included among the extraordinary expenses) corresponding to ~114,000 EUR

Minor deviations affected the governance costs as well as the budget for the human resources, IT, finances, and administration departments.

The office staff salaries exceeded budget by ~8%, primarily due to unfavourable currency exchange rate fluctuations occurring towards the end of the year and to adjustments of the social charges.

The result for non-cash and extraordinary items shows a further loss of 879,980 EUR, leading to a total loss of 1,433,193 EUR. Although some of these losses are unrealised, such as the customary depreciation of the office building in Geneva, a large portion is due to a major cleanup of our books, which led to identify some administrative errors, such as the undeclared VAT for the London Congress of 2022, and some double invoicing (both from providers and to sponsors). These unfortunate issues underline the impelling need to set up an Internal Control System. The latter is a set of rules and procedures whereby all financial operations conducted by EASL employees are traceable

and carried out in conformity with the GB decisions, the EASL strategy, and the Swiss law. Some practices are already well established at the organisation, while others must be developed further and implemented gradually. The Internal Control System team will conduct periodical controls of our books and processes, allowing identifying deviations from the approved budget. This approach will help protecting our assets, ensuring that our financial reporting is accurate, reliable, and compliant with the Swiss laws, improving the operational efficiency, preventing mistakes, managing risks and uncertainties, and identifying areas of improvement of our business operations. A voluntary external audit will also set in place, to allow for a thorough appraisal of all our future financial operations.

Because of the above, our net worth has suffered another loss with respect to 2022, although this was partially mitigated during the second half of the year, following some strict control of expenses, and based on the situation discussed at the June General Assembly. This has prompted major structural adjustments have been put in place following the thorough analysis and proposals of the Business Analysis Task Force, as already explained in this Report by our Secretary General and Vice-Secretary General, resulting in the financial year 2024 budget structure that is promising a return to a more favourable financial outlook. This is the blueprint for the next three-year period that will help consolidating EASL treasury while maintaining business continuity.

The first signs of recovery are already evident from the forecast updated as of the first quarter of the financial year 2024, it witnesses strong revenues from our events, education and membership and delivery of the significant structural costs reductions to which we committed.

The 2023 financial accounts were audited by A. Gautier Société Fiduciaire, an external audit firm. The auditors confirmed that EASL's accounts were in good order and properly reflected the financial status of the association.

I express my gratitude to the entire EASL Office for their commitment, and the continuing efforts to support EASL activities.



TREASURER
Francesco Negro

Auditor's Report

**Declaration of balance sheet's completeness by
European Association for the Study of the Liver (EASL), Geneva
for the attention of the auditor's firm
A. Gautier, Société Fiduciaire SA
regarding the financial statement
for the business year 2023**

We deliver to you the present declaration of completeness in connection with your limited statutory examination of the financial statements (balance sheet, income statement and notes) of European Association for the Study of the Liver (EASL), Geneva for the business year ended 31 December 2023. The purpose of your statutory examination consists in ascertaining whether there exist any facts likely to incite to the conclusion that the financial statements and the proposal concerning the use of the available earnings do not comply with the law and the articles of incorporation. We recognize the responsibility of the Board for these financial statements. The Board has approved these financial statements in order for them to be communicated to the General Meeting. We confirm that the legal conditions for a limited statutory examination are complied with.

We herewith confirm to you, to the best of our knowledge, the elements mentioned hereinafter:

- The financial statements are in conformity with Swiss law and the articles of incorporation and, within this context, free of any material misstatements (erroneous recordings, valuations, descriptions or presentations, and omitted indications may also be part thereof).
- We have made all information, accounting records, proofs and commercial correspondence as well as the records of all general meetings and meetings of the Board available to you.
- European Association for the Study of the Liver (EASL), Geneva has conformed to all contractual agreements and legal provisions (e.g. concerning direct taxes, value-added tax, social insurances, environmental protection), the inobservance of which has a material impact on the financial statements.
- The information provided to you in order to verify the identity of bound parties is complete; moreover, the indication of the credit balances and debts regarding shareholders and group entity is complete and accurate.
- We have neither any plans or intention, nor any knowledge of any events giving rise to any notable doubts about the capacity of the entity to continue its activity ("Going Concern").
- We have communicated to you in details the constitution, dissolution and state of undisclosed reserves (Art. 959c, para. 1, ch.3 CO).
- We have neither any plans, nor any intention likely to materially modify the setting up of the balance sheet, the valuation or the representation of assets or liabilities in the financial statements.
- The entity is provably entitled to dispose of all activated assets. None thereof is being limited by any charges other than those mentioned in the financial statements (annotation in the annex).
- We have correctly recorded respectively presented all actual liabilities and conditional commitments (guarantees, cautionary obligations and comparable declarations regarding third parties) in the financial statements.

Auditor's Report

- All material events subsequent to the balance sheet's date are recorded respectively presented in the financial statements.
- Claims resulting from legal disputes or other controversies which are of a material importance for the assessment of the entity's financial statements were inexistent / are mentioned in the enclosure.
- We have presented to you all credit agreements. The conditions relating thereto were complied with on the balance sheet's date and are complied with on the date of the present declaration of completeness.
- The amount and purpose of own resources not freely available (e.g. reserves within the meaning of Art. 671 et seq. CO) are correctly recorded respectively presented in the financial statements.

**European Association for the Study
of the Liver (EASL)**

Geneva, May 27, 2024

Enclosures:

- Signed copy of financial statements ((balance sheet total CHF 11'122'952)
- Documents mentioned hereinbefore

2023 Financial Statements

Balance Sheet, as of 31st December

Assets	2023	2022
	EUR	EUR
Current assets		
Cash and cash equivalents	683,840	1,758,251
Accounts receivables and other receivables	2,194,267	684,363
Prepaid expenses and accrued income	618,996	978,039
Total current assets	3,497,103	3,420,653
Fixed assets		
Financial assets	3,676,832	3,499,877
Investments	-	-
Tangible fixed assets	4,704,611	3,865,326
Intangible fixed assets	92,848	-
Total fixed assets	8,474,290	7,365,203
Total assets	11,971,393	10,785,856
Liabilities and reserve funds	2023	2022
	EUR	EUR
Current liabilities		
Accounts payable	976,676	1,149,271
Other short-term liabilities	334,211	37,325
Deferred income and accrued expenses	1,564,361	761,279
Total current liabilities	2,875,248	1,947,876
Long-term liabilities		
Long-term provisions	1,436,594	783,698
Total long-term liabilities	1,436,594	783,698
Allocated funds		
Unused restricted fund *Note 8	38,184	282,400
Total allocated funds	38,184	282,400
Equity		
Voluntary retained earnings	2,771,883	5,960,795
Reserve fund	5,000,000	5,000,000
Translation difference on reserve fund	1,108,497	-
Translation difference	174,182	-
Profit/Loss for the period	-1,433,193	-3,188,912
Total equity	7,621,368	7,771,883
Total liabilities and reserve funds	11,971,393	10,785,857

Profit and loss account

	2023 EUR	2022 EUR
Operating income		
Events	9,031,631	8,434,701
Education & Science	380,604	392,284
Association & Community Services (incl. Memberships)	812,513	791,241
Publishing	1,342,246	1,125,841
Policy, Public Health and Advocacy	128,561	121,367
Net building revenue		16,040
Total operating income	11,695,555	10,826,198
Operating expenses	*Note 2	
Events	-5,657,652	-6,483,377
Education & Science	-270,822	-380,998
Association & Community Services (incl. Memberships)	-510,049	-729,232
Publishing	-591,882	-590,237
Policy, Public Health and Advocacy	-222,952	-216,078
Governance	-381,507	-359,611
Total operating expenses	*Note 3	-8,773,693
Margin I	4,060,692	2,052,505
Personnel expenses	-4,100,611	-3,607,125
Margin II	-39,919	-1,554,620
Overhead (IT, HR, Finance, Administration & Office)		
IT	-197,315	-268,262
Human Resources	-101,534	-70,873
Finance	-96,605	-51,955
Administration & Office	-117,839	-44,469
Total overhead expenses	*Note 3	-435,559
EBITDA	-553,213	-1,554,620
Depreciation and value adjustments on fixed assets	-263,030	-251,136
EBIT	-816,244	-2,241,315
Financial income and expenses		
Financial expenses	-6,379	-44,379
Financial income	-	117,914
Gain or loss of exchange rate	-336,352	-
Other financial expenses	-	-554,415
Foreign exchange result	-	-160,629
Total financial income and expenses	*Note 4	-641,509
Result from ordinary activities before taxes	-1,158,975	-2,882,825
Annex charges	-53,244	-
Expenses on building EASL	-535	-
Loss on financial investment	-14,012	-
Loss of value / financial investment	-38,697	-
Annex income	83,411	-
Building operating revenue	19,685	-
Products realised / financial investments	63,726	-

Extraordinary, non-recurring or prior-period expenses	*Note 5	-745,920	-
Exceptional, unique or off/prior period income and expenses		-745,920	-150,795
Extraordinary, non-recurring or prior-period income	*Note 5	442,842	-150,795
Exceptional, unique or off/prior period income and expenses		442,842	-150,795
Result before taxes		-1,431,886	-3,033,619
Direct taxes	*Note 6	-1,307	
Net result after changes in funds		-1,433,193	-3,188,912
Change in funds			
Allocation of funds		-	-155,292
Total changes in funds		-	-155,292
Net result after changes in funds		-1,433,193	-3,188,912

Notes to the 2023 financial statements

General principles

Accounting principles applied in the preparation of the financial statements

These financial statements have been prepared in accordance with the provisions of commercial accounting as set out in the Swiss Code of Obligations (Art. 957 to 963b CO, effective since 1 January 2013). Significant balance sheet items are accounted for as follows:

Accounts receivable

Accounts receivable are amounts due from parties for services performed in the ordinary course of business. If collection is expected in one year or less (or in the normal operating cycle of the business if longer), they are classified as current assets.

These receivables are valued at their nominal values. Credit default risks are accounted for by specific and general allowances. General allowances are recognised for items that have not yet been considered with a specific allowance. The general allowance is based on the assumption that the default risk increases as the debt becomes increasingly overdue.

Recognition of revenue

The main revenue stream of EASL is the events sponsorship by industries and the event registration fees, mostly from the EASL Congress (the main event). EASL generates other revenues from scientific publications and the association membership fees.

Membership fees are recognised in the accounting period in which the fees relate to.

Congress revenue is mainly composed of fees received from participants and sponsors and recognised based on the contract specifications when the following conditions are all met:

- the amounts can be measured reliably,
- it is probable that the Association will receive future economic benefits.

Non-current assets and leases

Property, plant, and equipment are valued at purchase cost, less any depreciation required by generally accepted accounting principles. Depreciation is charged on a straight line basis over the useful life of the fixed asset. The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the income statement.

The useful lives of assets have been determined as follows:

Type of assets	Useful life
Building	30 years
Furniture, Fixtures and Equipment	10 years
Computer & Hardware	3 years
Intangible Assets	3 years

Foreign currencies

The functional currency being the CHF from 2023, the accounts are disclosed in CHF. All financial information are presented in CHF. The financial situation of the Association can only be presented in CHF for statutory purposes. The values in EUR (Euro) are disclosed for information only.

The method of translating financial statements is based on the following principles:

1. Translation of Assets and Liabilities:

Assets and liabilities are translated using the closing rate, which is the exchange rate in effect at the end of the reporting period, except for the below point

2. Translation of Equity:

Equity is converted at historical rates, meaning the exchange rates in effect at the time the equity was acquired or constituted.

3. Translation of the Income Statement:

Items in the Income statement (revenues and expenses) are converted using the average rate for the period, representing the average exchange rates during the fiscal year.

4. Translation of Free Reserves and Endowment Capital:

Free reserve elements are converted at the historical rate as of the end of 2018, the date of their constitution in EUR (see context above). Endowment capital is converted at the most recent EUR closing rate, ie. the rate at the end of 2022.

5. Translation of Real Estate and Depreciation:

Real estate assets and their depreciation, which has been recalculated since acquisition, are converted using the historical rate at the time of purchase in Swiss francs in order to disclose their legal historical value. This ensures the tax neutrality particularly necessary in this case. For fiscal purposes, it is crucial that tax bases are established consistently and that gains/losses are accurately disclosed.

6. Exchange Differences on Transactions:

Resulting exchange differences are accounted for by impacting the Income statement for the period.

7. Euro disclosure:

For comparison purposes and to facilitate the reading of the financial statements, we have decided to add the euro equivalent of all items. These figures are for indicative purposes only. The principle used to calculate the EUR equivalents is the same as explained before.

This method aims to provide a more accurate and consistent disclosure of the company's financial position. For reasons of presentation consistency, the Notes figures of the comparative period have been also adapted to the new disclosures.

Foreign currency		Profit and loss statement
2023	EUR/CHF	0.9717
2022	EUR/CHF	1.0241
2021	EUR/CHF	1.0824
2020	EUR/CHF	1.0824
2019	EUR/CHF	1.1276

The exchange rates used for balance sheet items are the rates prevailing on December 31; the exchange rates used for transactions conducted during the course of the year and for items in the profit and loss statement are average rates for the financial year.

For reasons of simplification, from 2023 onwards and in accordance with Swiss law, the financial statements will be drawn up in Swiss francs and expressed in euros.

Details, analyses, and explanations to the financial statements

The European Association for the Study of the Liver ("EASL") is an Association registered in Geneva (2018), previously in Zurich (2017), Switzerland. The number of full-time equivalents did not exceed 50 on an annual average basis.

The presentation has been slightly changed versus previous version and comparative numbers have been modified in accordance.

Receivables and liabilities

Receivables and liabilities towards direct or indirect participants and management bodies and entities in which there is a direct or indirect participation must in each case be shown separately on the balance sheet or in the notes to the financial statements (art. 959a para. 4 CO). This only applies if these items are not presented in the balance sheet as suggested.

Mortgage schedules

Commitments on the building - Rue Daubin 7:

- n° 10527 of 30.09.2008 for CHF 2,100,000 – First Row
- n° 10527 of 30.09.2008 for CHF 1,500,000 – Second Row
- n° 2013-752 of 030.12.2012 for CHF 200,000 – Third Row

Pension liabilities

On 31 December 2023, none, as payments were done on time without issues

Collateral for third-party liabilities	2023 CHF	2023 EUR	2022 CHF	2022 EUR
Guarantee obligations (Concerns business credit card limits)	67,868	73,000	67,868	73,000

Total amount resulting from the dissolution of replacement reserves and the material dissolution of excess hidden reserves

No hidden reserves were released in the year under review.

Significant events occurring after the balance sheet date

Non-existent

Significant events occurring during the reporting year

The recovery of normal activities, especially face to face events, following the COVID-19 did not reach budget assumptions, specifically concerning paid registration.

In 2023, our financial investments increased in value to represent EUR 176'955.

Fees paid and accrued to the auditor	2023 CHF	2023 EUR	2022 CHF	2022 EUR
Audit services	28,000	28,817	25,226	25,105

Note 1**Prepaid expenses and accrued income**

A prepaid expense results from a business making advanced payments for goods or services to be received in the future. Prepaid expenses are initially recorded as assets, but their value is expensed over time onto the income statement. After the benefits of the assets are realised over time, the amount is then released to P&L (i.e. recorded as an expense). Prepaid expenses are, in nature, short term assets. However, for the needs of EASL's business model, it can occur that some advanced payments for goods or services will be received in the mid-term future (i.e. two to five years ahead).

	2023 CHF	2023 EUR	2022 CHF	2022 EUR
Prepaid for the upcoming year	506,668	544,981	280,830	284,400
Mid-term prepayments	-	-	135,901	137,629
Accrued income	68,812	74,015	549,032	556,011
Suspens account	-	-	-	-
Prepaid expenses and accrued income	575,481	618,996	965,764	978,039

Note 2**Operating income**

	2023 CHF	2023 EUR	2022 CHF	2022 EUR
Events	8,775,590	9,031,631	-	-
Education & Science	369,814	380,604	-	-
Association & Community Services (including Memberships)	789,479	812,513	-	-
Publishing	1,304,194	1,342,246	-	-
Policy, Public Health and Advocacy	124,916	128,561	-	-
EASL Congress	-	-	7,537,757	7,501,627
Membership	-	-	713,360	709,941
Journal of Hepatology	-	-	1,131,263	1,125,841
Sponsors - (un)restricted funds	-	-	231,583	230,473
Net building revenue	-	-	13,129	13,066
Small conferences	-	-	1,285,292	1,279,131
Other revenues	-	-	-34,045	-33,882
Total operating income	11,363,994	11,695,555	10,878,339	10,826,198

Note 3**Other operating expenses**

	2023 CHF	2023 EUR	2022 CHF	2022 EUR
Events	-5,497,262	-5,657,652	-	-
Education & Science	-263,144	-270,822	-	-
Association & Community Services (including Memberships)	-495,590	-510,049	-	-
Publishing	-575,103	-591,882	-	-
Policy, Public Health and Advocacy	-216,631	-222,952	-	-
Governance	-370,691	-381,507	-	-
EASL Congress	-	-	-5,892,921	-5,864,676
Liver Cancer Summit	-	-	-103,205	-102,711
NAFLD Summit	-	-	-380,325	-378,503
Small conferences (Monothematic/Special conference)	-	-	-138,151	-137,489
Education and Scientific Activities	-	-	-382,833	-380,998
Marketing and Communication	-	-	-182,605	-181,729
Membership, Fellowships and Registry Grants	-	-	-550,139	-547,502
Journal of Hepatology	-	-	-593,080	-590,237
EU Advocacy / Policy and Public Affairs	-	-	-217,119	-216,078
GB Meetings and Honorarium	-	-	-357,571	-373,771
Total operating expenses	-7,418,420	-7,634,864	-8,815,950	-8,773,693

Note 4

Financial income and expenses	2023 CHF	2023 EUR	2022 CHF	2022 EUR
Financial expenses	-6,199	-6,379	-	-
Financial income	-	-	-	-
Gain or loss of exchange rate	-326,817	-336,352	-	-
Other financial expenses	-	-	-	-
Foreign exchange result	-	-	-	-
Financial income	-	-	117,626	117,062
Financial expenses	-	-	-48,823	-48,589
Interest of mortgage	-	-	-44,593	-44,379
Unrealised financial gains on bonds	-	-	-4,914	-4,890
Unrealised financial loss on bonds	-	-	-502,833	-500,423
Foreign exchange gain	-	-	-161,063	-160,291
Total financial income and expenses	-333,015	-342,732	-644,599	-641,509

Note 6**Explanations of extraordinary, non-recurring or prior period items in the profit and loss statement**

Non-existent

Note 6**Explanations of extraordinary, non-recurring or prior period items in the profit and loss statement**

	2023 CHF	2023 EUR
Extraordinary or prior-period expenses		
Prov. 2022 UK VAT (VAT + Interest + Penalty)	-603,843	-621,461
Remaining opened invoices 2019/20/21/22	-64,689	-66,576
SeeThrough SA - Facture No 20232010 / 1004 - Offsite HR advice (MGE) - Closing 2022	-12,750	-13,122
Suppliers adjustment CHF au 31.12.2023 (cleaning prior years: 2019-2020-2021-2022)	- 9,582	-9,861
Pmt facture - WILTON PARK EXECUTIVE AGENCY - INV 10907 - EASL	-4,249	-4,373
Odier Halpérin Steinmann Sàrl - Convention d'Accord.	-16,500	-16,981
Small other items	-13,161	-13,545
Total extraordinary expenses	-724,773	-745,920
2022 Total extraordinary, non-recurring expenses	-251,197	-249,993
2021 Total extraordinary from prior-periods expenses	-201,674	-200,707

Extraordinary or prior-period income	2023 CHF	2023 EUR
Source tax collection commission	5,461	5,620
JHEP Reports 2022 royalty	51,429	52,930
Industry revenue previous period (Boehringer Ingelheim, Merck Sharp, Takeda, Siemens...)	174,686	179,782
Cancellation of income from two industry invoices (2019/2020 period) that were counted in 2022 (Abbvie & Alexion)	-84,943	-87,422
Income adjustment ILC 2022 registrations (from Congrex)	24,596	25,314
Cancelling duplicate supplier invoices entered in previous years	4,483	4,641
Social security reimbursements	85,506	88,001
Dissolution of restricted funds (MICROB-PREDICT, LiverScreen, DECISION, MSD, Gilead)	112,930	116,224
EU VAT adjustment	7,577	7,798
Reversal of provisions (customer losses, HR tribunal action)	32,862	33,821
Small other items	15,702	16,160
Total extraordinary income	430,288	442,842

2022 Total extraordinary, non-recurring income	100,402	99,921
--	---------	--------

2021 Total extraordinary from prior-periods income	86,004	79,559
--	--------	--------

Note 6

Direct taxes

EASL benefits from a tax exemption; the tax paid in 2023 concerns a contribution to the public service in the sector of electronic media.

Note 7

Details of attribution and use of allocated funds

We have received funding of CHF 35,500 (EUR 38'184) for the GENIAL project.

OUR PARTNERS & SPONSORS

Our Partners



Our Sponsors



EASL Office
Home of Hepatology
7 rue Daubin
1203 Geneva
Switzerland
+41(0)22 807 03 60
easloffice@easloffice.eu
www.easl.eu

	Regular Individuals located in Europe (WHO definition)	EUR 250
	Corresponding Individuals located in non-European countries (WHO definition)	EUR 250
	Trainees & Postdoc Up to and including 35 years of age. Proof of age and trainee status required	EUR 50
	Undergraduate students Proof of enrolment required	Free
	Nurses & AHPs / Patients Proof of status required - Except for Patients	EUR 25
	Emeritus 65+ and EASL members for at least 10 years	EUR 25
	Emerging economy Proof of location of the home institution required	EUR 25
	Resource-limited economy Proof of location of the home institution required	Free

*Discover your membership
benefits now*




Become a member today



EASL CONGRESS

7-10 May 2025

Amsterdam, the Netherlands



Save the date!

#EASLCongress

easlcongress.eu